Preeclampsia. Part 1: Clinical and pathophysiologic considerations

Obstetrical and Gynecological Survey

Volumn 57, Issue 9, 2002, Pages 598-618

  Pridjian, Gabriella ^a   Puschett, Jules B ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; BETAMETHASONE; CALCIUM; DIAZEPAM; HOMOCYSTEINE; HYDRALAZINE; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; PHENYTOIN;

ACTIVATED PROTEIN C RESISTANCE; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING FACTOR 5 DEFICIENCY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE PREDISPOSITION; ECLAMPSIA; EDEMA; FETUS MORTALITY; HELLP SYNDROME; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MATERNAL MORBIDITY; MATERNAL MORTALITY; PATHOPHYSIOLOGY; PREDICTION; PREECLAMPSIA; PRENATAL CARE; PROGNOSIS; PROTEINURIA; REVIEW; SEIZURE; THROMBOPHILIA; FEMALE; FETUS DEATH; PREGNANCY; PREGNANCY COMPLICATION;

DIAGNOSIS, DIFFERENTIAL; FEMALE; FETAL DEATH; HELLP SYNDROME; HUMAN; HYPERTENSION; MATERNAL MORTALITY; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0036708375     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-200209000-00023     Document Type: Review

References (216)

1. Hypertension in pregnancy
2. Various. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy
3. Pregnancy-related mortality from preeclampsia and eclampsia
4. Various. Hypertension in pregnancy
5. Hypertension in pregnancy: Diagnosis and treatment
6. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986
7. Hypertension in pregnancy
8. Risk factors for preeclampsia/eclampsia among working women in Mexico City
9. The feasibility of a control population for a randomized controlled trial of seizure prophylaxis in the hypertensive disorder of pregnancy
10. Hypertensive disorders in pregnancy
11. Epidemiology of hypertension
12. Hypertension in pregnancy: Clinical-pathological correlation and remote prognosis
13. Placental transfer, fetomaternal interaction. Placental physiology and its role as go between
14. Increase in plasma volume during normal pregnancy
15. Cardiovascular hemodynamics in pregnancy. I. Blood and plasma volume in multiple pregnancy
16. Anemia during pregnancy
17. Control of volume and body tonicity
18. Adaptation of the maternal heart in pregnancy
19. Hemodynamic changes in pregnancy
20. Changes in hemodynamic, ventricular remodeling, and ventricular contractility during normal pregnancy: A longitudinal study
21. Cardiovascular function before, during, and after the first and subsequent pregnancies
22. Serial study of factors influencing changes in cardiac output during human pregnancy
23. Alterations in left ventricular mechanics in preeclampsia: Increased afterload or cardiomyopathy?
24. Position change and central hemodynamic profile during normal third-trimester pregnancy and post partum
25. Maternal blood volume and cardiac output during pregnancy: A hypothesis of endocrinologic control
26. A longitudinal study of cardiac output in normal human pregnancy
27. Serial assessment of the cardiovascular system in normal pregnancy: Role of arterial compliance and pulsatile arterial load
28. Hemodynamic changes in pregnancy
29. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy
30. Vascular reactivity to angiotensin II and norepinephrine in pregnant and nonpregnant women
31. The nature of pressor responsiveness to angiotensin II in human pregnancy
32. Calcium, nitric oxide, and preeclampsia
33. Cardiovascular responses to circulating catecholamines in normal pregnancy and in pregnany-induced hypertension
34. Variability of arterial blood pressure in normal and hypertensive pregnancy
35. Blood pressure survey in normal pregnancy
36. Studies on blood pressure during pregnancy. Influence of parity and age
37. Hypertension in women
38. Preeclampsia and neonatal outcomes in chronic hypertension: Comparison between white and black women
39. Chronic hypertension and pregnancy
40. Toxemia and hypertension
41. Fetal outcome in a trial of antihypertensive treatment in pregnancy
42. Final report of study on hypertension during pregnancy: The effects of specific treatment on the growth and development of the children
43. Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy
44. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy
45. A controlled trial of the treatment of hypertension in pregnancy: Labetalol compared with methyldopa
46. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy
47. An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development
48. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy
49. Pregnancy in 211 patients with mild chronic hypertension
50. Chronic hypertension in pregnancy
51. The prognosis of pregnancy in women with chronic hypertension
52. Chronic hypertension in pregnancy
53. Expansion of intravascular volume and fetal outcome in patients with chronic hypertension and pregnancy
54. Antecedents of cerebral palsy in very low-birth weight infants
55. Placental Physiology in Disease States. Fetomaternal Interactions: Placental physiology and Its Role as Go Between
56. Proteinuric hypertension in a pregnant baboon: Was this preeclampsia?
57. True pregnancy toxemia (preeclampsia) in the guinea pig (Cavia porcellus)
58. Placental infarction: A sign of preeclampsia in a patas monkey (Erythrocebus patas)
59. Discovery of a spontaneous genetic mouse model of preeclampsia
60. Introduction, history, controversies, and definitions
61. The syndrome of preeclampsia
62. Incidence and predictors of severe obstetric morbidity: Case-control study
63. Maternal mortality: Confidential enquiries into maternal deaths in the United Kingdom
64. Preterm delivery for maternal or fetal indications: Maternal morbidity, neonatal outcome and late sequelae in infants
65. MOS HIP. McMaster outcome study of hypertension in pregnancy
66. Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia
67. Various. Maternal mortality - United States, 1982-1996
68. History and epidemiology of preeclampsia-eclampsia
69. Some observations on the incidence of preeclampsia
70. A multivariate analysis of risk factors for preeclampsia
71. Changing paternity and the risk of preeclampsia in the subsequent pregnancy
72. Change in paternity: A risk factor for preeclampsia in multiparas
73. The interval between pregnancies and the risk of preeclampsia
74. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception
75. The rate of severe preeclampsia is increased in triplet as compared to twin gestations
76. Risk factors for preeclampsia in twin pregnancies: A population-based cohort study
77. Antenatal human parvovirus B19 infection and nonimmune hydrops fetalis presenting as severe preeclampsia
78. Spontaneous resolution of nonimmune hydrops fetalis secondary to Parvovirus B19 infection
79. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia
80. Increased frequency of genetic thrombophilia in women with complications of pregnancy
81. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome
82. Management of pregnancy in antiphospholipid syndrome
83. The HELLP syndrome at 16 weeks gestation: Possible association with the antiphospholipid syndrome
84. Inherited thrombophilias in pregnant patients: Detection and treatment paradigm
85. HELLP syndrome and factor V Leiden
86. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia
87. Preeclampsia and genetic risk factors for thrombosis: A case-control study
88. Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies
89. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation
90. Underlying disorders associated with severe early-onset preeclampsia
91. Hyperhomocysteinaemia: A risk factor for preeclampsia?
92. Pregnancy complications are frequent in long-chain 3-hydroxylacyl-coenzyme A dehydrogenase deficiency
93. Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency
94. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Variable expressivity of maternal illness during pregnancy and unusual presentation with infantile cholestasis and hypocalcaemia
95. Altered lipid metabolism in preeclampsia and HELLP syndrome: Links to enhanced platelet reactivity and fetal growth
96. A class I antigen, HLA-G, expressed in human trophoblasts
97. Analysis of the role of HLA-G in preeclampsia
98. Immune maladaption in the etiology of preeclampsia: A review of corroborative epidemiologic studies
99. The role of the spiral arteries in the pathogenesis of preeclampsia
100. Implantation and the placenta: Key pieces of the development puzzle
101. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and fetal growth retardation
102. Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo
103. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adherion phenotype. Once cause of defective endovacular invasion in this syndrome?
104. Regulation of human placental development by oxygen tension
105. Pathology and pathophysiology of preeclampsia: Alterations in volume homeostasis
106. Ascites. A portent of cardiopulmonary complications in the preeclamptic patient with the syndrome of hemolysis, elevated liver enzymes, and low platelets
107. The bulbar conjunctival vascular bed in the toxemias of pregnancy
108. The Parkland Memorial Hospital protocol for treatment of eclampsia: Evaluation of 245 cases
109. Maternal hemodynamics in normal and preeclamptic pregnancies: A longitudinal study
110. Maternal central hemodynamics in hypertensive disorders of pregnancy - A longitudinal study
111. CT demonstration of resolution of hepatic lesions in HELLP syndrome: A case report
112. Hepatic infarction in preeclampsia as part of the HELLP syndrome: CT appearance
113. Liver disease in pregnancy
114. Orthotopic liver transplantation for complicated HELLP syndrome. Case report and review of the literature
115. Primary focal segmental glomerulosclerosis: Pathology, histological variants, and pathogenesis
116. The effect of Benemid on uric acid excretion in normal pregnancy and in preeclampsia
117. Uric acid and endogenous creatinine clearance studies in normal pregnancy and toxemias of pregnancy
118. The kidney in toxemia of pregnancy: A clinical and pathologic study based on renal biopsies
119. The prognosis of the fetus in relation to the serum uric acid in toxaemia of pregnancy
120. Renal and cardiovascular alterations
121. Acute renal failure in pregnancy
122. Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction
123. Blindness associated with preeclampsia and eclampsia
124. Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction
125. The pathogenesis of eclamptic lesions
126. Early platelet consumption in preeclampsia
127. Evidence of accelerated platelet production and consumption in nonthrombocytopenic preeclampsia
128. Markers for endothelial injury, clotting and platelet activation in preeclampsia
129. Urinary thromboxane metabolites in preeclampsia
130. Maternal levels of prostacyclin, thromboxane, vitamin E and lipid peroxides throughout normal pregnancy
131. Preeclampsia as chronic disseminated intravascular coagulation. Study of two parameters: Thrombin-antithrombin III complex and D-dimers
132. Eclampsia. VIII. Risk factors for maternal morbidity
133. Eclampsia I. Observations from 67 recent cases
134. Proteinuria and outcome of 444 pregnancies complicated by hypertension
135. Hypertension-hypotension in pregnancy. Correlation with fetal outcome
136. Measurement of uterine blood flow and uterine metabolism
137. The maternal placental blood flow in normotensive and hypertensive women
138. Estimation of uterine blood flow in normal human pregnancy at term
139. Abruptio placentae: Risk factors and perinatal outcome
140. Antecedents of cerebral palsy in very low-birth weight infants
141. Aggressive or expectant management of severe preeclampsia at 28 to 32 weeks' gestation: A randomized controlled trial
142. How often does maternal preeclampsia-eclampsia incite thrombocytopenia in the fetus?
143. Extracellular fluid volumes in pregnancy-induced hypertension
144. Inadequacy of dipstick proteinuria in hypertensive pregnancy
145. The role of observer error in antenatal dipstick proteinuria analysis
146. Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy
147. Screening for consumptive coagulopathy in preeclampsia
148. Calcium supplementation in mild preeclampsia remote from term: A randomized double-blind clinical trial
149. Diagnosis of preeclampsia
150. Eclampsia: A 13-year experience at a United States tertiary care center
151. Eclampsia in the United Kingdom
152. Preeclampsia into eclampsia: Toward a new paradigm
153. Epidemiology of eclampsia
154. Cerebral imaging in eclampsia: Magnetic resonance imaging versus computed tomography
155. Cerebral edema complicating eclampsia
156. Management of eclampsia in the accident and emergency department
157. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: A severe consequence of hypertension in pregnancy
158. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome)
159. Obstetrical anaesthesia for patients with the syndrome of haemolysis, elevated liver enzymes and low platelets
160. Current understanding of severe preeclampsia, pregnancy-associated hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, hemolysis, elevated liver enzymes, and low platelets syndrome, and postpartum acute renal failure: Different clinical syndromes or just different names?
161. Imitators of preeclampsia and eclampsia
162. Renal biopsy and pregnancy
163. The kidney and hypertension in pregnancy: Twenty exciting years
164. Renal biopsy during pregnancy. To "b - or not to b - ."
165. Bleeding after renal biopsy in pregnancy
166. Pathology of the kidney, liver, and brain
167. Monitored outpatient management of mild gestational hypertension remote from term
168. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: A randomized controlled trial
169. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: A randomized controlled trial
170. A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome
171. Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP (hemoysis, elevated liver enzymes, and thrombocytypenia) syndrome
172. Individually determined postpartum magnesium sulfate therapy with clinical parameters to safely and cost-effectively shorten treatment for preeclampsia
173. Preeclampsia
174. A preliminary report on the intravenous use of magnesium sulphate in puerperal eclampsia
175. Magnesium for preeclampsia and eclampsia
176. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia
177. Treatment of hypertensive diseases in pregnancy - General recommendations and long-term oral therapy
178. Prevention or early treatment of preeclampsia
179. The combination of magnesium sulfate and nifedipine: A cause of neuromuscular blockade
180. Report of the National High Blood Pressure Education Program working group on high blood pressure in pregnancy
181. Randomized comparison of general and regional anesthesia for cesarean delivery in pregnancies complicated by severe preeclampsia
182. Potential complications of spinal and epidural anesthesia for obstetrics
183. Spinal versus epidural anesthesia for cesarean section in severely preeclamptic patients: A retrospective survey
184. Caritis Sn Safety of labor epidural anesthesia for women with severe hypertensive disease
185. 3
186. Influence of blood pressure changes with and without proteinuria upon outcome of pregnancy
187. Pregnancy outcome in 303 cases with severe preeclampsia
188. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women
189. Low-dose aspirin therapy to prevent preeclampsia
190. Low-dose aspirin to prevent preeclampsia in women at high risk
191. CLASP: A randomised trial of Low-dose aspirin for the prevention and treatment of preeclampsia among 9364 pregnant women
192. Barbados Los Dose Aspirin Study in Pregnancy. A randomized trial for the prevention of preeclampsia and its complications
193. Prevention of preeclampsia: A big disappointment
194. Calcium deficiency and toxemia of pregnancy
195. Calcium supplementation to prevent hypertensive disorders of pregnancy
196. Calcium supplementation reduces the risk of pregnancy-induced hypertension in an Andes population
197. Calcium supplementation and the risk of preeclampsia in Ecuadorian pregnant teenagers
198. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems
199. The effect of garlic tablet on plasma lipids and platelet aggregation in nulliparous pregnants at high risk of preeclampsia
200. Dietary supplementation with primrose oil or fish oil does not change urinary excretion of prostacyclin and thromboxane metabolites in preeclamptic women
201. Nonmedical prevention of preeclampsia
202. Effect of antioxidants on the occurrence of preeclampsia in women at increased risk: A randomized trial
203. The remote prognosis of eclamptic women
204. The remote prognosis in toxemia of pregnancy
205. Severe preeclampsia-eclampsia in young primigravid women: Subsequent pregnancy outcome and remote prognosis
206. The recurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsequent gestations
207. Pregnancies complicated by HELLP Syndrome: Subsequent pregnancy outcome and long-term prognosis
208. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome